Gilead Purchases FDA Priority Review Voucher For $125M
NPR: Gilead Buys Shortcut For FDA Drug Review For $125 Million
“…In an auction, Gilead Sciences, a maker of HIV and hepatitis medicines, just bought a coupon good for the accelerated review of a drug of the company’s choice from Knight Therapeutics, a Canadian company. The priority review voucher entitles Gilead to move a drug of its choice through the FDA four months faster than the normal track. … The legal shortcut was created in 2007 as a reward for companies developing drugs for specific neglected tropical diseases…” (Hensley, 11/19).